Security
Enzon Pharmaceuticals, Inc. Common Stock · ENZN
ENZNOTCCommon stockHistorical · closed Mar 25, 2026CIK 727510Updated Nov 6, 2026
Name history
ENZON PHARMACEUTICALS, INC. · through Mar 25, 2026ENZON PHARMACEUTICALS INC · through Feb 23, 2016ENZON PHARMACEUTICALS INC · through Mar 22, 2006ENZON PHARMACEUTICAL INC · through Dec 10, 2002ENZON INC · through Dec 9, 2002
Current security for this SEC filerVISK · OTC
ENZN price & chart
Historical security
This listing closed Mar 25, 2026. Live provider charts are shown only for current listings.
Current security: VISK
About the company
Viskase Holdings, Inc., through its subsidiaries, operates in the casing product segment of the food industry. Viskase is a worldwide leader in the production and sale of cellulosic, fibrous and plastic casings for the processed meat and poultry industry.
In the news
No coverage from other publishers is available.
Recent filings
10-Q filing
10-Q filing
8-A12G filing
Entry into a Material Definitive Agreement · Material Modification to Rights of Security Holders · Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year · Regulation FD Disclosure
Items 1.01, 3.03, 5.03, 7.01, 9.01
10-Q filing
Show 5 more recent filings
Financial Statements and Exhibits
Items 9.01
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements
Items 5.02
10-K/A filing
Entry into a Material Definitive Agreement · Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement
Items 1.01, 2.03, 9.01
Changes in Registrant's Certifying Accountant
Items 4.01, 9.01
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 43,693,000Source | 47,276,000Source | 424,483,000Source | 44,780,000Source | 46,994,000Source | 428,874,000Source | 45,521,000Source | 46,829,000Source | 42,813,000Source | 47,169,000Source | 47,702,000Source | 47,589,000Source |
| Property, Plant and EquipmentUSD | — | — | 147,653,000Source | — | — | 142,951,000Source | — | — | — | — | — | — |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 43,256,000Source | 46,633,000Source | 7,911,000Source | 44,294,000Source | 46,229,000Source | 28,619,000Source | 44,966,000Source | 45,988,000Source | 42,574,000Source | 46,859,000Source | 47,012,000Source | 46,982,000Source |
| Assets, CurrentUSD | 43,667,000Source | 46,970,000Source | 227,337,000Source | 44,738,000Source | 46,638,000Source | 234,581,000Source | 45,521,000Source | 46,469,000Source | 42,813,000Source | 47,152,000Source | 47,343,000Source | 47,387,000Source |
| LIABILITIES AND EQUITY | ||||||||||||
| Stockholders’ equity: | ||||||||||||
| Common Stock, Value, IssuedUSD | 742,000Source | 742,000Source | 143,000Source | 742,000Source | 742,000Source | 143,000Source | 742,000Source | 742,000Source | 742,000Source | 742,000Source | 742,000Source | 742,000Source |
| Retained Earnings (Accumulated Deficit)USD | -72,230,000Source | -69,820,000Source | -23,632,000Source | -71,406,000Source | -70,074,000Source | -18,570,000Source | -70,416,000Source | -70,350,000Source | -73,301,000Source | -69,892,000Source | -70,670,000Source | -72,043,000Source |
| Stockholders' Equity Attributable to ParentUSD | -923,000Source | 2,762,000Source | 186,800,000Source | 432,000Source | 3,039,000Source | 192,201,000Source | 1,953,000Source | 3,294,000Source | -2,525,000Source | 3,008,000Source | 3,505,000Source | 3,407,000Source |
| Additional Paid in Capital, Common StockUSD | 70,565,000Source | 71,840,000Source | 267,959,000Source | 71,096,000Source | 72,371,000Source | 267,959,000Source | 71,627,000Source | 72,902,000Source | 70,034,000Source | 72,158,000Source | 73,433,000Source | 74,708,000Source |
| Liabilities and EquityUSD | 43,693,000Source | 47,276,000Source | 424,483,000Source | 44,780,000Source | 46,994,000Source | 428,874,000Source | 45,521,000Source | 46,829,000Source | 42,813,000Source | 47,169,000Source | 47,702,000Source | 47,589,000Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 540,000Source | 438,000Source | 123,630,000Source | 803,000Source | 410,000Source | 116,937,000Source | 554,000Source | 521,000Source | 731,000Source | 1,678,000Source | 1,714,000Source | 1,699,000Source |
| Accounts Payable, CurrentUSD | 331,000Source | 331,000Source | 39,424,000Source | 331,000Source | 331,000Source | 36,893,000Source | 331,000Source | 331,000Source | 331,000Source | 331,000Source | 331,000Source | 331,000Source |
| Additional Financial Items | ||||||||||||
| Accrued Liabilities, CurrentUSD | 209,000Source | 107,000Source | 25,495,000Source | 472,000Source | 79,000Source | 24,792,000Source | 223,000Source | 190,000Source | 400,000Source | 72,000Source | 108,000Source | 93,000Source |
| Dividends Payable, CurrentUSD | — | — | — | — | — | — | — | — | — | 1,275,000Source | 1,275,000Source | 1,275,000Source |
| Goodwill | — | — | —Source | — | — | —Source | — | — | — | — | — | — |
| Accounts Receivable, after Allowance for Credit Loss, Current | — | — | —Source | — | — | —Source | — | — | — | — | — | — |
| Inventory, Net | — | — | —Source | — | — | —Source | — | — | — | — | — | — |
| Operating Lease, Right-of-Use Asset | — | — | —Source | — | — | —Source | — | — | — | — | — | — |
| Other Assets, Noncurrent | — | — | —Source | — | — | —Source | — | — | — | — | — | — |
| Accumulated Other Comprehensive Income (Loss), Net of Tax | — | — | —Source | — | — | —Source | — | — | — | — | — | — |
| Operating Lease, Liability, Current | — | — | —Source | — | — | —Source | — | — | — | — | — | — |
| Operating Lease, Liability, Noncurrent | — | — | —Source | — | — | —Source | — | — | — | — | — | — |
| Stockholders' Equity Attributable to Noncontrolling Interest | — | — | —Source | — | — | —Source | — | — | — | — | — | — |
| Long-term Debt, Excluding Current Maturities | — | — | —Source | — | — | —Source | — | — | — | — | — | — |
| Long-term Debt, Current Maturities | — | — | —Source | — | — | —Source | — | — | — | — | — | — |
| Long-term Debt, Excluding Current Maturities | — | — | —Source | — | — | —Source | — | — | — | — | — | — |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Deferred Income Tax Expense (Benefit)USD | — | — | 16,000Source | 50,000Source | — | 42,000Source | 34,000Source | 17,000Source | 17,000Source | 342,000Source | -157,000Source | -202,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -16,315,000Source | 129,000Source | -3,010,000Source | 1,122,000Source | 1,305,000Source | -659,000Source |
| Cash flows from financing activities: | ||||||||||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | 44,748,000Source | 7,188,000Source | -1,275,000Source | -1,275,000Source | -1,275,000Source | — |
| Payments of Ordinary Dividends, Common StockUSD | — | — | — | — | — | — | — | 1,275,000Source | 1,275,000Source | 1,275,000Source | 1,275,000Source | — |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | 19,402,000Source | 49,000Source | -4,285,000Source | -153,000Source | 30,000Source | -659,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | 43,256,000Source | 46,633,000Source | 7,911,000Source | 8,912,000Source | 28,619,000Source | 5,753,000Source | 42,574,000Source | 46,859,000Source | 47,012,000Source | 46,982,000Source |
| Supplemental disclosure of cash flow information: | ||||||||||||
| Income Taxes Paid, NetUSD | — | — | — | — | — | — | 315,000Source | 277,000Source | 2,000Source | — | — | — |
| Additional Financial Items | ||||||||||||
| Share-based Payment Arrangement, ExpenseUSD | — | — | — | — | — | — | — | — | — | 0Source | 0Source | 0Source |
| Dividends Payable, CurrentUSD | — | — | — | — | — | — | — | — | — | 1,275,000Source | 1,275,000Source | 1,275,000Source |
| Income Tax Expense (Benefit)USD | — | — | 16,000Source | 49,000Source | 305,000Source | 14,353,000Source | 748,000Source | -1,412,000Source | 19,000Source | 347,000Source | -156,000Source | -200,000Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -824,000Source | 254,000Source | -5,062,000Source | -20,246,000Source | -6,689,000Source | -13,585,000Source | -3,409,000Source | 778,000Source | 1,373,000Source | -186,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | -1,355,000Source | -277,000Source | -5,062,000Source | -20,246,000Source | -6,689,000Source | -13,585,000Source | -5,533,000Source | -497,000Source | 98,000Source | -1,461,000Source |
| Operating ExpensesUSD | — | — | 1,304,000Source | 351,000Source | — | 1,533,000Source | — | 1,002,000Source | 5,311,000Source | 1,353,000Source | 1,044,000Source | 1,058,000Source |
| Other Interest and Dividend IncomeUSD | — | — | 496,000Source | 654,000Source | — | 501,000Source | — | 497,000Source | 1,921,000Source | 2,452,000Source | 2,261,000Source | — |
| Proceeds from Stock Options ExercisedUSD | — | — | — | — | — | — | — | — | — | 0Source | 0Source | 0Source |
| Net Income (Loss), Including Portion Attributable to Noncontrolling Interest | — | — | — | — | —Source | —Source | —Source | —Source | — | — | — | — |
| Depreciation, Depletion and Amortization | — | — | — | — | — | — | —Source | —Source | — | — | — | — |
| Increase (Decrease) in Accounts Receivable | — | — | — | — | — | — | —Source | —Source | — | — | — | — |
| Increase (Decrease) in Inventories | — | — | — | — | — | — | —Source | —Source | — | — | — | — |
| Increase (Decrease) in Accounts Payable | — | — | — | — | — | — | —Source | —Source | — | — | — | — |
| Net Cash Provided by (Used in) Investing Activities | — | — | — | — | — | — | —Source | —Source | — | — | — | — |
| Interest Paid, Excluding Capitalized Interest, Operating Activities | — | — | — | — | — | — | —Source | —Source | — | — | — | — |
| Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents | — | — | — | — | — | — | —Source | —Source | — | — | — | — |
| Amortization of Debt Issuance Costs | — | — | — | — | — | — | —Source | —Source | — | — | — | — |
| Amortization of Intangible Assets | — | — | — | — | —Source | —Source | —Source | —Source | — | — | — | — |
| Depreciation | — | — | — | — | — | — | —Source | —Source | — | — | — | — |
| General and Administrative Expense | — | — | — | — | —Source | —Source | —Source | —Source | — | — | — | — |
| Goodwill | — | — | — | — | —Source | — | —Source | — | — | — | — | — |
| Inventory Write-down | — | — | — | — | — | — | — | —Source | — | — | — | — |
| Net Income (Loss) Attributable to Noncontrolling Interest | — | — | — | — | —Source | —Source | —Source | —Source | — | — | — | — |
| Other Nonoperating Income (Expense) | — | — | — | — | —Source | —Source | —Source | —Source | — | — | — | — |
| Payments of Financing Costs | — | — | — | — | — | — | —Source | —Source | — | — | — | — |
| Proceeds from Issuance of Common Stock | — | — | — | — | — | — | —Source | —Source | — | — | — | — |
| Proceeds from Issuance of Long-term Debt | — | — | — | — | — | — | —Source | — | — | — | — | — |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total RevenueUSD | — | — | — | — | — | — | — | — | — | 26,000Source | — | 26,000Source |
| Operating Income (Loss)USD | — | — | -1,304,000Source | -351,000Source | -2,015,000Source | -2,630,000Source | -4,333,000Source | -14,401,000Source | -5,311,000Source | -1,327,000Source | -1,044,000Source | -1,032,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | — | — | -808,000Source | 303,000Source | -4,828,000Source | -5,905,000Source | -5,974,000Source | -15,006,000Source | -3,390,000Source | 1,125,000Source | 1,217,000Source | -386,000Source |
| Income Tax Expense (Benefit)USD | — | — | 16,000Source | 49,000Source | 305,000Source | 14,353,000Source | 748,000Source | -1,412,000Source | 19,000Source | 347,000Source | -156,000Source | -200,000Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -824,000Source | 254,000Source | -5,062,000Source | -20,246,000Source | -6,689,000Source | -13,585,000Source | -3,409,000Source | 778,000Source | 1,373,000Source | -186,000Source |
| Earnings Per Share, BasicUSD per share | — | — | -0.02Source | 0Source | -0.35Source | -3.74Source | -0.84Source | -2.65Source | -0.07Source | -0.01Source | 0Source | -0.02Source |
| Earnings Per Share, DilutedUSD per share | — | — | -0.02Source | 0Source | -0.35Source | -3.74Source | -0.84Source | -2.65Source | -0.07Source | -0.01Source | 0Source | -0.02Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 74,215,000Source | 74,215,000Source | 14,331,620Source | 5,419,340Source | 7,931,249Source | 5,126,972Source | 74,215,000Source | 74,215,000Source | 74,215,000Source | 74,215Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 74,215,000Source | 74,215,000Source | 14,331,620Source | 5,419,340Source | 7,931,249Source | 5,126,972Source | 74,215,000Source | 74,215,000Source | 74,215,000Source | 74,215Source |
| Additional Financial Items | ||||||||||||
| Current Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 2,000Source | 5,000Source | 1,000Source | 2,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | — | — | — | — | — | — | — | — | -3,390,000Source | — | — | — |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | -1,355,000Source | -277,000Source | -5,062,000Source | -20,246,000Source | -6,689,000Source | -13,585,000Source | -5,533,000Source | -497,000Source | 98,000Source | -1,461,000Source |
| Operating ExpensesUSD | — | — | 1,304,000Source | 351,000Source | — | 1,533,000Source | — | 1,002,000Source | 5,311,000Source | 1,353,000Source | 1,044,000Source | 1,058,000Source |
| Other General and Administrative ExpenseUSD | — | — | 229,000Source | 351,000Source | — | 314,000Source | — | 1,002,000Source | 1,356,000Source | 1,353,000Source | 1,044,000Source | 1,058,000Source |
| Other Interest and Dividend IncomeUSD | — | — | 496,000Source | 654,000Source | — | 501,000Source | — | 497,000Source | 1,921,000Source | 2,452,000Source | 2,261,000Source | — |
| Preferred Stock Dividends, Income Statement ImpactUSD | — | — | 531,000Source | 531,000Source | — | 531,000Source | — | 531,000Source | 2,124,000Source | 1,275,000Source | 1,275,000Source | 1,275,000Source |
| Total Revenue | — | — | — | — | —Source | —Source | —Source | —Source | — | — | — | — |
| Cost of Goods and Services Sold | — | — | — | — | —Source | —Source | —Source | —Source | — | — | — | — |
| Selling, General and Administrative Expense | — | — | — | — | —Source | —Source | —Source | —Source | — | — | — | — |
| Other Nonoperating Income (Expense) | — | — | — | — | —Source | —Source | —Source | —Source | — | — | — | — |
| Net Income (Loss) Attributable to Noncontrolling Interest | — | — | — | — | —Source | —Source | —Source | —Source | — | — | — | — |
| Amortization of Intangible Assets | — | — | — | — | —Source | —Source | —Source | —Source | — | — | — | — |
| Common Stock, Dividends, Per Share, Declared | — | — | — | — | — | — | —Source | — | — | — | — | — |
| General and Administrative Expense | — | — | — | — | —Source | —Source | —Source | —Source | — | — | — | — |
| Gross Profit | — | — | — | — | —Source | —Source | —Source | —Source | — | — | — | — |
| Interest Income (Expense), Nonoperating, Net | — | — | — | — | —Source | —Source | —Source | —Source | — | — | — | — |
| Research and Development Expense | — | — | — | — | —Source | —Source | —Source | —Source | — | — | — | — |
| Selling and Marketing Expense | — | — | — | — | —Source | —Source | —Source | —Source | — | — | — | — |
Offerings
Registration 333-293019
Filing attachments
tm2613382d1_ex4-1.htm · 8-K · 2026-05-05
EX-4.1 3 tm2613382d1_ex4-1.htm EXHIBIT 4.1 Exhibit 4.1 Section 382 Rights Agreement Dated as of May 5, 2026 by and between VISKASE HOLDINGS, INC. and CONTINENTAL STOCK TRANSFER & TRUST COMPANY as Rights Agent TABLE OF CONTENTS Page # Section 1. Certain Definitions 1 Section 2. Appointment of Rights Agent 11 Section 3…
Read attachment ↗tm2613382d1_ex99-1.htm · 8-K · 2026-05-05
EX-99.1 4 tm2613382d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Viskase Holdings, Inc. Adopts Tax Benefits Preservation Plan to Protect its NOL Assets and Shareholder Value Lombard, Illinois, May 5, 2026 - Viskase Holdings, Inc. (formerly known as Enzon Pharmaceuticals, Inc.) (the “Company”) today announced that its Board of Directors (the “Board”) adopted a tax benefits preservation plan (the “Section 382 Rights Plan”) designed to protect the availability of Viskase’s net operating loss carry…
Read attachment ↗tm2612647d1_ex99-1.htm · 8-K/A · 2026-05-01
EX-99.1 2 tm2612647d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 CONSOLIDATED FINANCIAL STATEMENTS OF VISKASE COMPANIES, INC. AND SUBSIDIARIES Financial Statements Report of Independent Certified Public Accountants Consolidated Balance Sheets as of December 31, 2025 and 2024 ────────────────────────────────────────────────── Consolidated Statements of Operations for the years ended December 31, 2025, 2024 and 2023 ──────────────────────────────────────────────────────── Co…
Read attachment ↗tm2612647d1_ex99-2.htm · 8-K/A · 2026-05-01
EX-99.2 3 tm2612647d1_ex99-2.htm EXHIBIT 99.2 Exhibit 99.2 UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION Introduction On March 26, 2026 (the “Closing Date”), Viskase Holdings Inc. (formerly known as Enzon Pharmaceuticals, Inc.) (the “Combined Company”) consummated the previously announced transactions pursuant to the Agreement and Plan of Merger, dated as of June 20, 2025, by and among Enzon Pharmaceuticals Inc. (“Enzon”), EPSC Acquisition Corp. (“Merger Sub”) and Viskase C…
Read attachment ↗tm269894d1_ex99-1.htm · 8-K · 2026-03-26
EX-99.1 4 tm269894d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Enzon Pharmaceuticals Completes Merger with Viskase Companies, Inc. Combined company will operate as Viskase Holdings, Inc. LOMBARD, Illinois, March 26, 2026 (GLOBE NEWSIRE) - Enzon Pharmaceuticals, Inc. (OTCQB: ENZN), (“Enzon,” or the “Company”), today announced the completion of the previously announced merger pursuant to which Viskase Companies, Inc. (OTC Pink Limited: VKSC) (“Viskase”) merged with and into a wholly owned subsid…
Read attachment ↗tm267492d15_ex4-1.htm · 8-K · 2026-03-24
EX-4.1 4 tm267492d15_ex4-1.htm EXHIBIT 4.1 EXHIBIT 4.1 ELEVENTH AMENDMENT TO THE SECTION 382 RIGHTS AGREEMENT by and between ENZON PHARMACEUTICALS, INC. and CONTINENTAL STOCK TRANSFER & TRUST COMPANY, as Rights Agent This ELEVENTH AMENDMENT TO THE SECTION 382 RIGHTS AGREEMENT (this “Eleventh Amendment”) is made and entered into March 23, 2026, and is effective immediately, by and between Enzon Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and Continental Stock Transf…
Read attachment ↗